poisar

Stocks · News reference

CytomX Therapeutics Says FDA Granted Fast Track Designation To Varseta-M For Relapsed/Refractory Metastatic Colorectal Cancer; Plans Registrational Monotherapy Study Start In 1H 2027

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CTMX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Not Specified

    CytomX Therapeutics to Present at Upcoming September Investor Conferences

    CytomX Therapeutics announced that management will participate in three major healthcare investor conferences in September 2026, including Wells Fargo, Cantor Global Healthcare, and Morgan Stanley conferences. The company will host fireside chats and one-on-one investor meetings at these events. Live webcasts will be available on CytomX's website.

    CTMX